Developing an ELISA using serotype-specific antigens from selected pneumococcal strains of own selection

H. C. Slotved; J. N. Jacobsen; H. K. Møller; K. A. Krogfelt

doi:10.1016/j.vaccine.2006.09.028

Developing an ELISA using serotype-specific antigens from selected pneumococcal strains of own selection

H. C. Slotved^*, J. N. Jacobsen, H. K. Møller, K. A. Krogfelt

^*Corresponding author

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

Streptococcus pneumoniae (pneumococcus) is a significant cause of morbidity and mortality in infants and elderly people. Pneumococcal strains possess a polysaccharide capsule, and 90 different serotypes have been identified. The pneumococcal ELISA suggested by World Health Organization (WHO) guidelines is based on capsular serotypes included in the 23-valent polysaccharide vaccine (Pneumovax^®). Pneumococcal antigens were developed and applied in an ELISA, which elicited a low baseline cross-reaction with the common cell wall polysaccharide (C-Ps). The aim of this study was to develop an ELISA using type-specific antigens from S. pneumoniae strains with serotypes of own selection in order to quantify type-specific pneumococcal antibodies in human serum.

Originalsprog	Engelsk
Tidsskrift	Vaccine
Vol/bind	25
Udgave nummer	13
Sider (fra-til)	2513-2517
Antal sider	5
ISSN	0264-410X
DOI	https://doi.org/10.1016/j.vaccine.2006.09.028
Status	Udgivet - 22 mar. 2007
Udgivet eksternt	Ja

Link til dokument

10.1016/j.vaccine.2006.09.028

Citer dette

@article{971cc30dffd843dcb344f8801776a1a0,

title = "Developing an ELISA using serotype-specific antigens from selected pneumococcal strains of own selection",

abstract = "Streptococcus pneumoniae (pneumococcus) is a significant cause of morbidity and mortality in infants and elderly people. Pneumococcal strains possess a polysaccharide capsule, and 90 different serotypes have been identified. The pneumococcal ELISA suggested by World Health Organization (WHO) guidelines is based on capsular serotypes included in the 23-valent polysaccharide vaccine (Pneumovax{\textregistered}). Pneumococcal antigens were developed and applied in an ELISA, which elicited a low baseline cross-reaction with the common cell wall polysaccharide (C-Ps). The aim of this study was to develop an ELISA using type-specific antigens from S. pneumoniae strains with serotypes of own selection in order to quantify type-specific pneumococcal antibodies in human serum.",

keywords = "ELISA, Human sera, Pneumococcal antigens",

author = "Slotved, {H. C.} and Jacobsen, {J. N.} and M{\o}ller, {H. K.} and Krogfelt, {K. A.}",

year = "2007",

month = mar,

day = "22",

doi = "10.1016/j.vaccine.2006.09.028",

language = "English",

volume = "25",

pages = "2513--2517",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "13",

}

TY - JOUR

T1 - Developing an ELISA using serotype-specific antigens from selected pneumococcal strains of own selection

AU - Slotved, H. C.

AU - Jacobsen, J. N.

AU - Møller, H. K.

AU - Krogfelt, K. A.

PY - 2007/3/22

Y1 - 2007/3/22

N2 - Streptococcus pneumoniae (pneumococcus) is a significant cause of morbidity and mortality in infants and elderly people. Pneumococcal strains possess a polysaccharide capsule, and 90 different serotypes have been identified. The pneumococcal ELISA suggested by World Health Organization (WHO) guidelines is based on capsular serotypes included in the 23-valent polysaccharide vaccine (Pneumovax®). Pneumococcal antigens were developed and applied in an ELISA, which elicited a low baseline cross-reaction with the common cell wall polysaccharide (C-Ps). The aim of this study was to develop an ELISA using type-specific antigens from S. pneumoniae strains with serotypes of own selection in order to quantify type-specific pneumococcal antibodies in human serum.

AB - Streptococcus pneumoniae (pneumococcus) is a significant cause of morbidity and mortality in infants and elderly people. Pneumococcal strains possess a polysaccharide capsule, and 90 different serotypes have been identified. The pneumococcal ELISA suggested by World Health Organization (WHO) guidelines is based on capsular serotypes included in the 23-valent polysaccharide vaccine (Pneumovax®). Pneumococcal antigens were developed and applied in an ELISA, which elicited a low baseline cross-reaction with the common cell wall polysaccharide (C-Ps). The aim of this study was to develop an ELISA using type-specific antigens from S. pneumoniae strains with serotypes of own selection in order to quantify type-specific pneumococcal antibodies in human serum.

KW - ELISA

KW - Human sera

KW - Pneumococcal antigens

U2 - 10.1016/j.vaccine.2006.09.028

DO - 10.1016/j.vaccine.2006.09.028

M3 - Journal article

C2 - 17007972

AN - SCOPUS:33847621159

SN - 0264-410X

VL - 25

SP - 2513

EP - 2517

JO - Vaccine

JF - Vaccine

IS - 13

ER -